Vinpocetine

Last Updated: September 28 2022

Vinpocetine is a compound from the Periwinkle plant that is used as a cognitive protective and anti-aging agent. One of the more common of the nootropics, Vinpocetine may enhance blood flow and is touted to increase memory; this latter claim has not been investigated.

Vinpocetine is most often used for

Summary

Vinpocetine is a synthetic alkaloid derived from the periwinkle plant (specifically, synthesized from the molecule known as 'vincamine') that appears to have a track record of usage in European countries for the treatment of cognitive decline, stroke recovery, and epilepsy. Vinpocetine is also commonly used as a nootropic compound in the hopes that it may promote memory formation.

Vinpocetine is not fully absorbed, but what is absorbed peaks in the blood rapidly and easily enters the brain where it can exert its functions. The properties that appear to apply to oral vinpocetine supplementation include neuroprotection (against toxins and excess stimulation) and reducing neural inflammation, whereas the cognitive enhancement effect does not appear to be well supported by evidence at this point in time. While vinpocetine does appear to be effective in preventing toxins or stressors from causing amnesia, it is not yet demonstrated to inherently improve memory formation.

Vinpocetine also appears to have some efficacy against cognitive decline, but the amount of literature on this topic is much less than other drugs tested for this purpose (CDP-Choline or Alpha-GPC in particular). At least one study has noted an improvement in reaction time with a 40mg tablet of vinpocetine, which may be one of the only practically relevant improvements for healthy persons at this moment in time.

Infusions of vinpocetine do appear to enhance blood flow to the brain without inherently modifying pressure systemically, and this is thought (but not shown) to apply to oral ingestion. This would potentially reduce headaches caused by excessive pressure, and is in accordance with the traditional usage of the periwinkle plant (to reduce headaches).

Vinpocetine appears to have a role in neuroprotection and reducing neural inflammation, and for healthy persons it may potentially increase blood flow to the brain and improve reaction time (Limited evidence all around). The benefit of vinpocetine in memory formation is not yet proven, but it may protect the brain from amnesia

The mechanisms of vinpocetine are numerous. It appears to interact with several ion channels (sodium, potassium, and calcium) while tends to result in suppressive effects on neurotransmitter release and neuroprotection when dopamine or glutamate are suppressed (these two, when unnecessarily stimulated by toxins, can cause oxidative damage). It also interacts with alpha adrenergic receptors and the TPSO receptor, and while the exact benefit of these receptor interactions are not clear they are probably relevant since they occur at the same concentrations that the ion channel interactions do.

Vinpocetine is also a PDE1 inhibitor, which is a mechanism that is both cardioprotective and cognitive enhancing. Unfortunately, this inhibition occurs at a fairly large dose and may not apply to standard supplemental dosages of vinpocetine.

Similar to PDE1, an antidopaminergic potential of vinpocetine and direct inhibition of glutaminergic receptors both appear to occur at very high concentrations in vitro and may not be relevant to standard supplementation.

Vinpocetine is likely a modulator of ion channel activity, although there are some receptor interactions on alpha-adrenergic and TSPO that appear to be relevant. Other mechanisms including PDE1 inhibition or hindering glutaminergic/dopaminergic neurotransmission have been noted in vitro but at concentrations which are much higher and thus may not be relevant following oral ingestion of vinpocetine

Vinpocetine has been linked to fetal toxicity in a series of animal studies. Caution in warranted.

What else is Vinpocetine known as?
Note that Vinpocetine is also known as:
  • Vincamine
  • Vinca Minor
  • Periwinkle Extract
  • Cavinton (Brand Name)
  • Ethyl Apovincaminate
Dosage information

Vinpocetine is taken in the daily dosage range of 15-60mg, divided into three daily doses with meals. The standard low dose is 5mg at each of these three meals, with 20mg at each meal being seen as the higher end of efficacy. These doses are taken for the purposes of neuroprotection, enhancing cerebral blood flow, and reducing the rate of cognitive decline.

Doses in the higher end of that range (30-45mg acute dosages) may be useful for promoting cognition and memory formation in otherwise healthy persons, but there is not a lot of evidence looking at this claim.

Warning: for pregnant women, the equivalent of doses abouve 10 mg/d have been linked to fetal toxicity in animal studies. 10 mg/d may also be risky, especially when taking throughout an entire pregnancy.

Join our supplement information course

Examine Database: Vinpocetine
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

References
2.^Lörincz C, Szász K, Kisfaludy LThe synthesis of ethyl apovincaminateArzneimittelforschung.(1976)
5.^Patyar S, Prakash A, Modi M, Medhi BRole of vinpocetine in cerebrovascular diseasesPharmacol Rep.(2011)
6.^Bönöczk P, Gulyás B, Adam-Vizi V, Nemes A, Kárpáti E, Kiss B, Kapás M, Szántay C, Koncz I, Zelles T, Vas ARole of sodium channel inhibition in neuroprotection: effect of vinpocetineBrain Res Bull.(2000 Oct)
8.^Szakács T, Veres Z, Vereczkey LIn vitro-in vivo correlation of the pharmacokinetics of vinpocetinePol J Pharmacol.(2001 Nov-Dec)
9.^Grandt R, Beitinger H, Schaltenbrand R, Braun WVinpocetine pharmacokinetics in elderly subjectsArzneimittelforschung.(1989 Dec)
10.^Vereczkey L, Czira G, Tamás J, Szentirmay Z, Botár Z, Szporny LPharmacokinetics of vinpocetine in humansArzneimittelforschung.(1979)
11.^Sozański T, Magdalan J, Trocha M, Szumny A, Merwid-Ląd A, Słupski W, Karaźniewicz-Łada M, Kiełbowicz G, Ksiądzyna D, Szeląg AOmeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in ratsPharmacol Rep.(2011)
12.^Lohmann A, Dingler E, Sommer W, Schaffler K, Wober W, Schmidt WBioavailability of vinpocetine and interference of the time of application with food intakeArzneimittelforschung.(1992 Jul)
13.^Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JPPreparation and evaluation of self-microemulsifying drug delivery system containing vinpocetineDrug Dev Ind Pharm.(2009 May)
15.^Miskolczi P, Vereczkey L, Szalay L, Göndöc CEffect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acidEur J Clin Pharmacol.(1987)
16.^Chen J, Cai J, Tao W, Mei N, Cao S, Jiang XDetermination of apovincaminic acid in human plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detectionJ Chromatogr B Analyt Technol Biomed Life Sci.(2006 Jan 18)
17.^Vereczkey LPharmacokinetics and metabolism of vincamine and related compoundsEur J Drug Metab Pharmacokinet.(1985 Apr-Jun)
19.^Gulyás B, Halldin C, Sóvágó J, Sandell J, Cselényi Z, Vas A, Kiss B, Kárpáti E, Farde LDrug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetineEur J Nucl Med Mol Imaging.(2002 Aug)
22.^Gulyás B, Halldin C, Karlsson P, Chou YH, Swahn CG, Bönöck P, Paróczai M, Farde LBrain uptake and plasma metabolism of {11C}vinpocetine: a preliminary PET study in a cynomolgus monkeyJ Neuroimaging.(1999 Oct)
23.^Gulyás B, Halldin C, Sandell J, Karlsson P, Sóvágó J, Kárpáti E, Kiss B, Vas A, Cselényi Z, Farde LPET studies on the brain uptake and regional distribution of {11C}vinpocetine in human subjectsActa Neurol Scand.(2002 Dec)
27.^Hu C, Rhodes DGProniosomes: a novel drug carrier preparationInt J Pharm.(1999 Aug 5)
30.^Ahn HS, Crim W, Romano M, Sybertz E, Pitts BEffects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aortaBiochem Pharmacol.(1989 Oct 1)
31.^Hagiwara M, Endo T, Hidaka HEffects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscleBiochem Pharmacol.(1984 Feb 1)
32.^Rosdy B, Balázs M, Szporny LBiochemical effects of ethyl apovincaminateArzneimittelforschung.(1976)
37.^Zhou X, Dong XW, Crona J, Maguire M, Priestley TVinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channelsJ Pharmacol Exp Ther.(2003 Aug)
39.^Erdo SA, Molnár P, Lakics V, Bence JZ, Tömösközi ZVincamine and vincanol are potent blockers of voltage-gated Na+ channelsEur J Pharmacol.(1996 Oct 24)
42.^Vas A, Christer H, Sóvágó J, Johan S, Cselényi Z, Kiss B, Kárpáti E, Lars F, Gulyás BHuman positron emission tomography with oral 11C-vinpocetineOrv Hetil.(2003 Nov 16)
45.^Bukanova JV, Solntseva EI, Skrebitsky VGSelective suppression of the slow-inactivating potassium currents by nootropics in molluscan neuronsInt J Neuropsychopharmacol.(2002 Sep)
46.^Solntseva EI, Bukanova JV, Skrebitsky VGThe nootropic drug vinpocetine modulates different types of potassium currents in molluscan neuronsComp Biochem Physiol C Toxicol Pharmacol.(2001 Feb)
48.^Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan CVinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanismProc Natl Acad Sci U S A.(2010 May 25)
50.^Casellas P, Galiegue S, Basile ASPeripheral benzodiazepine receptors and mitochondrial functionNeurochem Int.(2002 May)
51.^Tárnok K, Kiss E, Luiten PG, Nyakas C, Tihanyi K, Schlett K, Eisel ULEffects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neuronsNeurochem Int.(2008 Dec)
53.^Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Márián T, Molnár T, Szakáll S, Trón L, Bereczki D, Csiba L, Fekete I, Kerényi L, Galuska L, Varga J, Bönöczk P, Vas A, Gulyás BEffects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET studyJ Neurol Sci.(2005 Mar 15)
54.^Szakáll S, Boros I, Balkay L, Emri M, Fekete I, Kerényi L, Lehel S, Márián T, Molnár T, Varga J, Galuska L, Trón L, Bereczki D, Csiba L, Gulyás BCerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET studyJ Neuroimaging.(1998 Oct)
61.^Szobor A, Klein MEthyl apovincaminate therapy in neurovascular diseasesArzneimittelforschung.(1976)
63.^van Staveren WC, Markerink-van Ittersum M, Steinbusch HW, de Vente JThe effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the ratBrain Res.(2001 Jan 12)
64.^Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SHEndothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticityProc Natl Acad Sci U S A.(1994 May 10)
66.^Paróczai M, Kiss B, Kárpáti EEffect of RGH-2716 on learning and memory deficits of young and aged rats in water-labyrinthBrain Res Bull.(1998 Mar 15)
67.^Gaál L, Molnár PEffect of vinpocetine on noradrenergic neurons in rat locus coeruleusEur J Pharmacol.(1990 Oct 23)
69.^Ishihara K, Katsuki H, Sugimura M, Satoh MIdebenone and vinpocetine augment long-term potentiation in hippocampal slices in the guinea pigNeuropharmacology.(1989 Jun)
71.^Nyakas C, Felszeghy K, Szabó R, Keijser JN, Luiten PG, Szombathelyi Z, Tihanyi KNeuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion modelCNS Neurosci Ther.(2009 Summer)
74.^Bhatti JZ, Hindmarch IVinpocetine effects on cognitive impairments produced by flunitrazepamInt Clin Psychopharmacol.(1987 Oct)
76.^Subhan Z, Hindmarch IPsychopharmacological effects of vinpocetine in normal healthy volunteersEur J Clin Pharmacol.(1985)
79.^Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, Porreca FInhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8Pain.(2002 Jan)
81.^Gold MS, Weinreich D, Kim CS, Wang R, Treanor J, Porreca F, Lai JRedistribution of Na(V)1.8 in uninjured axons enables neuropathic painJ Neurosci.(2003 Jan 1)
85.^Chikvaidze VN, Nikuradze VOThe role of adrenoreceptors in the mechanism of pharmacological action of cavintonUkr Biokhim Zh.(1987 May-Jun)
88.^Shih JC, Chen K, Ridd MJMonoamine oxidase: from genes to behaviorAnnu Rev Neurosci.(1999)
92.^Alexi T, Hughes PE, Faull RL, Williams CE3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegenerationNeuroreport.(1998 Aug 3)
94.^Villarán RF, Tomás-Camardiel M, de Pablos RM, Santiago M, Herrera AJ, Navarro A, Machado A, Cano JEndogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals productionNeurotoxicology.(2008 Mar)
95.^Zaitone SA, Abo-Elmatty DM, Elshazly SMPiracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in ratsIndian J Pharmacol.(2012 Nov-Dec)
96.^Erdö SL, Cai NS, Wolff JR, Kiss BVinpocetin protects against excitotoxic cell death in primary cultures of rat cerebral cortexEur J Pharmacol.(1990 Oct 23)
97.^Biró K, Kárpáti E, Szporny LProtective activity of ethyl apovincaminate on ischaemic anoxia of the brainArzneimittelforschung.(1976)
112.^Gulyás B, Halldin C, Vas A, Banati RB, Shchukin E, Finnema S, Tarkainen J, Tihanyi K, Szilágyi G, Farde L{11C}vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studiesJ Neurol Sci.(2005 Mar 15)
113.^Banati RBVisualising microglial activation in vivoGlia.(2002 Nov)
114.^Kassiou M, Meikle SR, Banati RBLigands for peripheral benzodiazepine binding sites in glial cellsBrain Res Brain Res Rev.(2005 Apr)
115.^Gulyás B, Tóth M, Schain M, Airaksinen A, Vas A, Kostulas K, Lindström P, Hillert J, Halldin CEvolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker {((11))C}vinpocetineJ Neurol Sci.(2012 Sep 15)
119.^Medina AEVinpocetine as a potent antiinflammatory agentProc Natl Acad Sci U S A.(2010 Jun 1)
120.^Zhao YY, Yu JZ, Li QY, Ma CG, Lu CZ, Xiao BGTSPO-specific ligand Vinpocetine exerts a neuroprotective effect by suppressing microglial inflammationNeuron Glia Biol.(2011 May)
121.^Mouton PR, Long JM, Lei DL, Howard V, Jucker M, Calhoun ME, Ingram DKAge and gender effects on microglia and astrocyte numbers in brains of miceBrain Res.(2002 Nov 22)
123.^Batarseh A, Papadopoulos VRegulation of translocator protein 18 kDa (TSPO) expression in health and disease statesMol Cell Endocrinol.(2010 Oct 7)
124.^Gulyás B, Vas A, Tóth M, Takano A, Varrone A, Cselényi Z, Schain M, Mattsson P, Halldin CAge and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with {11C}vinpocetineNeuroimage.(2011 Jun 1)
127.^Cai Y, Li JD, Yan CVinpocetine attenuates lipid accumulation and atherosclerosis formationBiochem Biophys Res Commun.(2013 May 10)
129.^Mitra S, Goyal T, Mehta JLOxidized LDL, LOX-1 and atherosclerosisCardiovasc Drugs Ther.(2011 Oct)
130.^Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan CUpregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate toleranceCirculation.(2001 Nov 6)
131.^Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai RHematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosisNat Med.(2002 Apr)
132.^Torsney E, Xu QResident vascular progenitor cellsJ Mol Cell Cardiol.(2011 Feb)
134.^Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel TRequirement for generation of H2O2 for platelet-derived growth factor signal transductionScience.(1995 Oct 13)
137.^Huang EW, Xue SJ, Zhang Z, Zhou JG, Guan YY, Tang YBVinpocetine inhibits breast cancer cells growth in vitro and in vivoApoptosis.(2012 Oct)
138.^Münzel T, Heitzer T, Kurz S, Harrison DG, Luhman C, Pape L, Olschewski M, Just HDissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery diseaseJ Am Coll Cardiol.(1996 Feb)
139.^Münzel T, Daiber A, Gori TNitrate therapy: new aspects concerning molecular action and toleranceCirculation.(2011 May 17)
140.^Feil R, Kleppisch TNO/cGMP-dependent modulation of synaptic transmissionHandb Exp Pharmacol.(2008)
144.^Hutter K, Deli L, Csomós I{Successful resuscitation from sudden death caused by Cavinton}Orv Hetil.(1980 Feb 17)
145.^Dany F, Merle L, Goudoud JC, Liozon F, Blanc P, Bouvot JC, Nicot G, Dangoumau J{Cardiac toxicity of vincamine: a seven cases report of ventricular arrhythmias by parenteral administration of vincamine (author's transl)}Therapie.(1981 Jan-Feb)
146.^van Hecke EContact sensitivity to vincamine tartrateContact Dermatitis.(1981 Jan)
149.^Waidyanatha S, Toy H, South N, Gibbs S, Mutlu E, Burback B, McIntyre BS, Catlin NSystemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transferToxicol Appl Pharmacol.(2018 Jan 1)